



**Planet Depos**<sup>®</sup>  
We Make It *Happen*<sup>™</sup>

---

# Transcript of Paul A. Bunn, Jr., M.D.

**Date:** July 11, 2017

**Case:** Apotex Inc., et al. -v- OSI Pharmaceuticals, Inc. (PTAB)

**Planet Depos**

**Phone:** 888.433.3767

**Email:** [transcripts@planetdepos.com](mailto:transcripts@planetdepos.com)

[www.planetdepos.com](http://www.planetdepos.com)

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22

UNITED STATES PATENT AND TRADEMARK OFFICE  
BEFORE THE PATENT TRIAL AND APPEAL BOARD  
APOTEX INC., APOTEX CORP., APOTEX PHARMACEUTICALS  
HOLDINGS INC., and APOTEX HOLDINGS, INC.,

Petitioners,

v.

OSI PHARMACEUTICALS, INC.,

Patent Owner,

---

U.S. Patent No. 6,900,221

---

Case No: IPR2016-01284

---

DEPOSITION OF PAUL A. BUNN, JR., M.D. - July 11, 2017

---

PURSUANT TO NOTICE, the deposition of  
PAUL A. BUNN, JR., M.D. was taken on behalf of the  
Petitioners at 1225 17th Street, Suite 2600, Denver,  
Colorado, on July 11, 2017, at 8:01 a.m., before Wendy  
C. Heath, Certified Realtime Reporter, Registered  
Professional Reporter and Notary Public within  
Colorado.

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22

A P P E A R A N C E S

For the Petitioners:

W. BLAKE COBLENTZ, ESQ.  
ERIC J. CHOI, ESQ.  
Cozen O'Connor PC  
1200 Nineteenth Street Northwest  
Washington, D.C. 20036

For the Patent Owner:

EMILY R. WHELAN, ESQ.  
KEVIN M. YURKERWICH, ESQ.  
Wilmer Cutler Pickering Hale and Dorr LLP  
60 State Street  
Boston, Massachusetts 02109

Also Present:

Andrea Tiglio, Ph.D.

I N D E X	
EXAMINATION OF PAUL A. BUNN, JR., M.D.: July 11, 2017	PAGE
By Mr. Coblentz	5
DEPOSITION EXHIBITS	INITIAL REFERENCE
Exhibit 1030 Petitioners' Notice of Deposition of Paul A. Bunn, M.D., Under 37 C.F.R., Section 42.53	9
Exhibit 1031 Journal of Clinical Oncology article: Phase I and Pharmacologic Study of OSI-774, an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, in Patients With Advanced Solid Malignancies	71
Exhibit 1032 Journal of Clinical Oncology article: A Randomized, Phase II, Biomarker-Selected Study Comparing Erlotinib to Erlotinib Intercalated With Chemotherapy in First-Line Therapy for Advanced Non-Small-Cell Lung Cancer	97
Exhibit 1033 Article: EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib	101
Exhibit 1034 Article: This \$7,800-a-month cancer drug caused rashes and rarely worked. Now Trump could make FDA approvals even easier	107
Exhibit 1035 Summary Minutes of Oncologic Drugs Advisory Committee, December 16, 2009	117

1	DEPOSITION EXHIBITS: (Previously marked)	
2	Exhibit 1001 Patent No: US 6,900,221 BI	42
3	Exhibit 1008 Provisional Application Cover Sheet and Provisional Application	12
4	Exhibit 1009 Patent Number 5,747,498	54
5	Exhibit 1010 Article: Anticancer drug targets: Growth factors and growth factor signaling	87
6		
7	Exhibit 1016 Article: Induction of Apoptosis and Cell Cycle Arrest by CP-358,774, an Inhibitor of Epidermal Growth Factor Receptor Tyrosine Kinase	90
8		
9		
10	Exhibit 2021 Declaration of Dr. Paul Bunn	10
11		
12	Exhibit 2024 American Society of Clinical Oncology Thirty-Fifth Annual Meeting, May 15-18, 1999, Atlanta, GA	76
13		
14	Exhibit 2036 Review: Targeting the Epidermal Growth Factor Receptor in Non-Small Cell Lung Cancer	67
15		
16		
17		
18		
19		
20		
21		
22		

# Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

## Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

## Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

## Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

## API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

## LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

## FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

## E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.